FEB 05, 2016 4:45 AM PST

Street Drugs for Treatment-Resistant Depression

WRITTEN BY: Cassidy Reich
Depression affects millions of  Americans and many of those people are taking some kind of medication. Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed antidepressant, but they are really not an ideal treatment. It can take 4-6 weeks for an SSRI to exert its beneficial effects, and for some living with depression, SSRIs don’t work at all. There are other treatments for depression (tricyclics, monoamine oxidase inhibitors, SNRIs), but they all act on the monoamine neurotransmitters (dopamine, serotonin, norepinephrine) and they can have horrible side effects. There is a lack of alternatives for treatment-resistant depression, and this is an especially big problem for those with comorbid alcoholism.

Alcoholism and depression are highly comorbid, but there is no united treatment for them. Usually, clinicians will treat one disorder and then the other, but that doesn’t account for the fact that the symptoms of one can make the symptoms of the other worse. Those with comorbid alcoholism and depression are more prone to be resistant to SSRI treatment, and so new therapeutics are needed to treat this especially vulnerable population.

Ketamine, a horse tranquilizer also known as the street drug “special k,”  has been getting a lot of attention recently because it is a fast-acting antidepressant. Unlike current antidepressants that can take weeks to work, ketamine can alleviate symptoms of depression in hours. Researchers at Vanderbilt University Medical Center have shown that, in an animal model of alcoholism-induced depression, ketamine administration can ameliorate symptoms of depression. Ketamine is a NMDA receptor antagonist, but it is competitive with alcohol at this receptor. What that means is, in addition to its “dissociative anesthetic” effects, ketamine has high abuse potential for alcoholics.

Because of this significant downside of ketamine, the Vanderbilt group also tested a  monoacylglycerol lipase (MAG) inhibitor. MAG lipase degrades 2-AG (2-arachidonoylglycerol), one of the endogenous ligands for the CB1 receptor. The endocannabinoid system has been implicated in depression and anxiety and, specifically, the Vanderbilt researchers showed that following alcohol exposure, there are elevated levels of 2-AG in parts of the brain that are involved in those disorders. Pharmacologically raising the levels of 2-AG to activate the CB1 receptor could alleviate the depressive symptoms and possibly reduce the cravings that come with withdrawal. Using the same animal model of alcohol-induced depression, treatment with a MAG lipase inhibitor reduced depressive behavior.

An upside of using an enzyme inhibitor to increase the amount of an endogenous agonist is that there will be no psychotropic effects. THC, the active compound in marijuana, is also a CB1 agonist, but the psychotropic effects aren’t desirable in a clinical setting. Another benefit of targeting CB1 is that alcohol does not bind to or affect this receptor at all. Unlike ketamine which can substitute for alcohol, cannabinoids, endogenous or otherwise, cannot, meaning that there is much, much lower abuse potential for alcoholics.

It is exciting to see researchers finally moving beyond the monoamine-focused treatments for depression. SSRIs and other similar drugs have helped so many people, but there are certain populations that these drugs don’t help. Treating comorbid alcoholism and depression or substance use disorder and depression is very difficult and requires a more integrated treatment plan. This a vulnerable population who would greatly benefit from a more effective therapeutic.
About the Author
  • Cassidy is a curious person, and her curiosity has led her to pursue a PhD in Pharmacology at the New York University Sackler Institute of Biomedical Sciences. She likes to talk about science way too much, so now she's going to try writing about it.
You May Also Like
OCT 07, 2020
Cancer
Delivering Cancer Drugs to Osteosarcoma with Nanoparticles
OCT 07, 2020
Delivering Cancer Drugs to Osteosarcoma with Nanoparticles
Over the years, cancer researchers have struggled not just with drug and diagnostic design, but with drug delivery. The ...
OCT 07, 2020
Neuroscience
Researchers Discover Molecular Mechanism for Memory Formation
OCT 07, 2020
Researchers Discover Molecular Mechanism for Memory Formation
Researchers from MIT have found that when the brain forms a new memory, neurons known as 'engram cells' encode t ...
OCT 14, 2020
Cancer
Using Plasma Scalpels with Chemotherapy Against Brain Cancer
OCT 14, 2020
Using Plasma Scalpels with Chemotherapy Against Brain Cancer
Cold atmospheric plasma is a relatively new technique that utilizes a tool that generates a sort of plasma scalpel, exce ...
OCT 21, 2020
Immunology
CNS's immune cells - Microglia are involved in the exacerbation of MS
OCT 21, 2020
CNS's immune cells - Microglia are involved in the exacerbation of MS
Multiple sclerosis (MS) is one of the most progressive autoimmune diseases that affect the central nervous system where ...
OCT 18, 2020
Cell & Molecular Biology
Small RNA is Connected to Bacterial Pathogenicity
OCT 18, 2020
Small RNA is Connected to Bacterial Pathogenicity
It's thought that as much as half of the global population carries a bacterium called Helicobacter pylori in their stoma ...
OCT 24, 2020
Genetics & Genomics
Cord Blood Samples Reveal More About the Genetics of Autism
OCT 24, 2020
Cord Blood Samples Reveal More About the Genetics of Autism
The activity of genes in our genome is controlled by many factors, one of which are chemical tags or structural changes ...
Loading Comments...